Diagnostic Or Test Agent Produces In Vivo Fluorescence Patents (Class 424/9.6)
  • Patent number: 11501544
    Abstract: An imaging flow cytometer device includes a housing holding a multi-color illumination source configured for pulsed or continuous wave operation. A microfluidic channel is disposed in the housing and is fluidically coupled to a source of fluid containing objects that flow through the microfluidic channel. A color image sensor is disposed adjacent to the microfluidic channel and receives light from the illumination source that passes through the microfluidic channel. The image sensor captures image frames containing raw hologram images of the moving objects passing through the microfluidic channel. The image frames are subject to image processing to reconstruct phase and/or intensity images of the moving objects for each color. The reconstructed phase and/or intensity images are then input to a trained deep neural network that outputs a phase recovered image of the moving objects. The trained deep neural network may also be trained to classify object types.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: November 15, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Aydogan Ozcan, Zoltan Gorocs
  • Patent number: 11472825
    Abstract: The present invention relates to a real-time fluorescence imaging sensor for measuring glutathione in cell organelles and a method for fabricating the same. More specifically, the present invention relates to a novel compound for measuring glutathione in cell organelles, a method for preparing the novel compound, a real-time fluorescence imaging sensor for measuring glutathione in cell organelles, which comprises the novel compound, a method for fabricating the imaging sensor, and a method of measuring glutathione in cell organelles by use of the imaging sensor. When the composition comprising the compound according to the present invention is used, it can measure the antioxidant activity of the organelle mitochondria or Golgi apparatus in living cells, particularly stem cells, and can screen highly active stem cells based on the results obtained by measuring the antioxidant activity of the cell organelle.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: October 18, 2022
    Assignee: CELL2IN, INC.
    Inventors: Heun Soo Kang, Hye Mi Kim, Ji Eun Song, Myoung Jin Kim, Ki Hang Choi
  • Patent number: 11458154
    Abstract: The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising: administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the individual.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: October 4, 2022
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • Patent number: 11454592
    Abstract: An object of the present invention is to provide a means for confirming whether a plant (for example, cannabis or tobacco) or a processed product thereof is a genuine product. The present invention provides a confirmation method including: an irradiation step (S11) of irradiating a plant or a processed product of the plant with light; a confirmation 5 step (S12) of confirming whether the plant or the processed product of the plant irradiated with light emits fluorescence; and a determination step (S13) of determining the plant or the processed product of the plant emitting fluorescence to be a genuine product and the plant or the processed product of the plant not emitting fluorescence to be a counterfeit product.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: September 27, 2022
    Assignee: NEC CORPORATION
    Inventor: Hiroki Matsuura
  • Patent number: 11369677
    Abstract: A composition is for use as a medicament. The composition contains nanoparticles, wherein the nanoparticles contain a polymer selected from the group consisting of PLGA, PLA, PGA, PCL and poly(meth)acrylates, or a lipid. Further, the composition may contain nanoparticles made of a polymer selected from PLGA, amino alkyl methacrylate copolymers, methacrylic acid copolymers, methacrylic ester copolymers, and ammonio alkyl methacrylate copolymers.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: June 28, 2022
    Inventor: Alf Lamprecht
  • Patent number: 11357216
    Abstract: The present invention relates to a method for promoting production of female embryos in fertilized eggs, comprising steps of: incubating said eggs; generating at least one type of energy with a predetermined energy profile; and simultaneously generating a pre-determined profile of a non-energy parameter by means of an energy generation device, applying both energy profile and the non-energy parameter to the eggs; and, collecting the eggs; wherein said method is non-toxic to the embryos, the application of both the energy profile and the non-energy parameter increases the fraction of females in the hatched chicks.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: June 14, 2022
    Assignee: N.R SOOS TECHNOLOGY LTD.
    Inventors: Mohamad Haj′ Nashat, Gadi Itshak Demer
  • Patent number: 11305021
    Abstract: Membrane-lytic block copolymers, micellar assemblies, pharmaceutical compositions, and related methods are described.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: April 19, 2022
    Assignee: University of Washington
    Inventors: Yilong Cheng, Suzie H. Pun
  • Patent number: 11298327
    Abstract: Methods and formulations are provided for treating or preventing arthritis, in particular osteoarthritis, where the formulation to be administered to a subject for treating or preventing arthritis comprises carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: April 12, 2022
    Assignee: Albert Einstein College of Medicine
    Inventors: Hui B. Sun, Daniel J. Leong, Neil J. Cobelli, David M. Hirsh, John A. Hardin, Karen E. Sperling, Sun J. Kim, David C. Spray, Chandan Guha, Marwa Choudhury
  • Patent number: 11293870
    Abstract: A vital stain for observation under multiphoton laser microscopy, the vital stain comprising one or more edible dye compounds.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: April 5, 2022
    Assignee: MIE UNIVERSITY
    Inventors: Akira Mizoguchi, Takeshi Fujiwara, Koji Tanaka, Shujie Wang, Kousyoku Sai, Kazushi Kimura
  • Patent number: 11291736
    Abstract: The pH-responsive ultrasensitive fluorescent nanoprobe is composed of pH-responsive matrix materials and fluorescent organic small molecule dyes. The pH-responsive matrix materials are calcium phosphate, calcium hydroxyphosphate, fluorapatite, calcium carbonate or ZIF series; the fluorescent organic small molecule dyes are positively charged dyes or negatively charged dyes. The preparation method includes: coating a positively charged dye with a negatively charged matrix material; coating a negatively charged dye with a negatively charged matrix material; and coating a negatively charged dye with a positively charged matrix material.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: April 5, 2022
    Assignee: XIDIAN UNIVERSITY
    Inventors: Zhongliang Wang, Yongdong Wang, Ruili Zhang, Qian Jia, Chaoqiang Qiao, Jie Tian
  • Patent number: 11285224
    Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: March 29, 2022
    Assignee: MediBeacon Inc.
    Inventors: Richard B. Dorshow, Steven J. Hanley, Phillip I. Tarr
  • Patent number: 11261236
    Abstract: The present invention relates to: a fusion peptide comprising a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide; and a use thereof and, more specifically, to: a fusion peptide in which a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide are sequentially linked; a composition for preventing or treating thrombotic disorders, containing the same as an active ingredient; a method for treating thrombotic disorders; and a therapeutic use. According to the present invention, CLT-sFt-?Pn DCNC as a novel plasmin-based thrombolytic nanocage has: an effect of targeting a site at which thrombus is present; a low sensitivity to inhibitors present in the circulatory system; pharmacological activity strongly destroying both arterial and venous thrombi; and no side effects of bleeding, and thus can be very useful in developing an agent for preventing or treating thrombotic disorders.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: March 1, 2022
    Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Soyoun Kim, Jun Young Seo, In San Kim
  • Patent number: 11253482
    Abstract: The present invention relates to a biodegradable multilayer nanocapsule for the delivery of at least one biologically active agent into at least one target cell consisting of at least two layers of at least two biodegradable polymers which are laid one onto the other and whereby the biologically active agent is layered onto a layer of a biodegradable polymer and covered with a further layer of a biodegradable polymer, whereby one biologically active agent is a nucleic acid.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: February 22, 2022
    Assignees: Albert-Ludwigs-Universitaet Freiburg, Queen Mary University of London
    Inventors: Gleb Sukhorukov, Irina Nazarenko, Yana Tarakanchikova, Toni Cathomen, Tatjana Cornu, Valentina Pennucci, Jamal Alzubi
  • Patent number: 11235168
    Abstract: This invention relates to a method of photodynamic therapy (PDT) for bladder cancer and its use as an adjuvant or neoadjuvant therapy in the treatment of bladder cancer. The invention provides a composition comprising hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof for use in a method of photodynamic therapy for bladder cancer, wherein said composition is instilled into the bladder of a patient in need of such treatment and the inside of said bladder is exposed to blue light having a fluence rate of 1.5 to 12.5 mW/cm2.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: February 1, 2022
    Assignee: PHOTOCURE ASA
    Inventors: Kjetil Hestdal, Aslak Godal
  • Patent number: 11214628
    Abstract: New monoclonal antibodies for use in pre-treatments prior to stem cell transplantations are disclosed. The antibodies may be used to kill malignant cells and/or stem cells prior to stem cell transplantation. The antibodies can be used for treating hematologic diseases and hematological malignancies, such as leukemia and MDS. The antibodies of the invention might be multi- or bi-specific, such as BiTEs.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: January 4, 2022
    Inventors: Michael Uhlin, Jonas Mattsson
  • Patent number: 11207427
    Abstract: Methods and systems for distinguishing an astrocytic human brain tumor from a non-astrocytic human brain tumor. In one embodiment, a method includes the steps of staining tumor tissue from a subject suspected of having a brain tumor with SR101 and visualizing the tissue stained with SR101 with a fluorescence imaging device to confirm an astrocytic or non-astrocytic tumor type. Advantageously, tumor tissue from a subject is stained ex vivo, and the staining and visualizing steps are performed intraoperatively so as to guide the surgeon and thereby minimize or eliminate the need for a subsequent surgery.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: December 28, 2021
    Assignee: Dignity Health
    Inventors: Joseph Georges, Nikolay Martirosyan, Peter Nakaji
  • Patent number: 11185278
    Abstract: Methods, compositions and systems are provided for the imaging of cavity/tissue lesions, including without limitation cavity/tissue malignant lesions, e.g. cancers of the skin, mouth, colon, digestive system cervix, bladder, lung, etc.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: November 30, 2021
    Assignee: Orlucent, Inc.
    Inventors: Catherine M. Shachaf, Amit Shachaf
  • Patent number: 11187651
    Abstract: Methods and devices are provided to provide clean signals even in the presence of spectral interference. At least some of these methods can be applied for cases when interfering signals are to be accounted for. These cases include, but are not limited to, hemolysis detection, icterus detection, and assays. They can be implemented in with data collected with spectrophotometers, instruments that can collect absorbance values at the few wavelengths of interest, and, in the case of the method based on background subtraction, simple imaging setups with only two filters (such as but not limited to narrow-band and wide-band) per absorption peak of interest.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: November 30, 2021
    Assignee: Labrador Diagnostics LLC
    Inventor: Toan Huynh
  • Patent number: 11156615
    Abstract: The present subject matter provides glucose biosensors as well as compositions, devices, and methods comprising such biosensors.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: October 26, 2021
    Assignee: Duke University
    Inventors: Homme W. Hellinga, Malin J. Allert
  • Patent number: 11116835
    Abstract: Anti-Epstein Barr Virus (EBV) antibodies and vaccines are described herein. The antibodies and vaccines can be used to treat and/or reduce the risk of EBV infection and to treat and/or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: September 14, 2021
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Andrew McGuire
  • Patent number: 11097250
    Abstract: Methods of synthesizing crystalline metal-organic frameworks (MOFs) comprising polytopic organic linkers and cations, where each linker is connected to two or more cations, are provided. In the disclosed methods, the linkers are reacted with a compound of formula MnXm, where M is cationic Be, Mg, Ca, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Zr, Nb, Mo, Ru, Rh, Pd, Cd, or Hf, X is anionic, n and m are integers. The reacting is buffered by a buffer devoid of metal coordinating functionality when the pKa of the anion is below a threshold related to the lowest pKa of the linker. The reacting is optionally not buffered when the pKa of the anion is at or above this threshold. The disclosed methods lead to product phase MOF in which crystal growth is controlled leading to control over molecular diffusion.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: August 24, 2021
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, EXXONMOBIL RESEARCH AND ENGINEERING COMPANY
    Inventors: Simon C. Weston, Jeffrey R. Long, Joseph M. Falkowski, Kristen Colwell, Rodolfo Torres
  • Patent number: 11096986
    Abstract: The present invention shows that the isolated NFL-TBS40-63 peptide is highly specific for neural stem cells. It is therefore presented here for use in a method for detecting these cells in vitro or in vivo, for addressing chemical compounds or biological materials to said cells, or for treating neurodegenerative disorders or brain tumours.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: August 24, 2021
    Assignees: Universite D'Angers, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Joel Eyer, Claire Lepinoux-Chambaud
  • Patent number: 11091646
    Abstract: Luminescent reporter compounds that are rotaxanes having the structure where B—Z—C is a reporter molecule based on a squaraine type molecule, or similar reporter, and K is a macrocycle that encircles and interlocks with the reporter molecule. Applications of the reporter compounds are provided, as well as reactive intermediates used to synthesize the reporter compounds, and methods of synthesizing the reporter compounds.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: August 17, 2021
    Assignee: SETA BioMedicals, LLC
    Inventors: Dmytro V. Kobzev, Olga S. Kolosova, Olena M. Obukhova, Olga M. Semenova, Rostyslav P. Svoyakov, Anatoliy L. Tatarets, Ewald A. Terpetschnig
  • Patent number: 11091643
    Abstract: The present invention is generally directed to the synthesis and use of fluorophores. It is more specifically directed to the synthesis and use of deuterated fluorophores. In one case, the present invention provides a compound of the structure shown in FIG. 44.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: August 17, 2021
    Assignee: Howard Hughes Medical Institute
    Inventors: Luke Lavis, Jonathan B. Grimm
  • Patent number: 11077210
    Abstract: The instant invention provides near-infrared fluorescent biological contrast agents and methods of using them.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: August 3, 2021
    Assignees: Beth Israel Deaconess Medical Center, Georgia State University Research Foundation Inc.
    Inventors: John V. Frangioni, Hak Soo Choi, Maged M. Henary
  • Patent number: 11027027
    Abstract: Embodiments of the invention include a novel synthesis of the translocator protein (TSPO) ligands, and methods of imaging a molecular events. Also disclosed are compounds for treatment of diseases, including cancer.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: June 8, 2021
    Assignee: Vanderbilt University
    Inventors: H. Charles Manning, Yiu-Yin Cheung, Jason R. Buck, Jun Li
  • Patent number: 11001562
    Abstract: The instant invention provides near-infrared fluorescent nerve contrast agents and methods of using them.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: May 11, 2021
    Assignees: Beth Israel Deaconess Medical Center, Georgia State University Research Foundation Inc.
    Inventors: John V. Frangioni, Hak Soo Choi, Maged M. Henary
  • Patent number: 10996170
    Abstract: Systems and methods for measuring short wave infrared fluorescence and autofluorescent signals are disclosed.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: May 4, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Moungi G. Bawendi, Oliver Thomas Bruns, Tulio A. Valdez, Jessica Ann Carr, Daniel Franke, Marianne Aellen
  • Patent number: 10987388
    Abstract: Provided are engineered phages populations, which are homogeneous in length, as well as methods of making and methods of using such phages. Also provided are engineered chlorotoxin-phages as well as their methods of making and using. The disclosed homogeneous phage populations and chlorotoxin-phages may be used, for example, for treating and/or imaging tumors, such as central nervous system tumors.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: April 27, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Angela M. Belcher, Uyanga Tsedev, Fred Lam
  • Patent number: 10973933
    Abstract: Disclosed herein are nanoparticles for diagnosis or treatment of tumors. The nanoparticles include: (a) a core including a Prussian blue dye; and (b) a shell obtained by partially or completely coating a surface of the Prussian blue core with albumin, thereby diagnosing a tumor by a nuclear magnetic resonance imaging apparatus and a near-infrared fluorescence imaging apparatus and necrotizing a tumor by a combined photothermal-photodynamic effect.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: April 13, 2021
    Assignee: GWANGJU INSTITUTE OE SCIENCE AND TECHNOLOGY
    Inventors: Giyoong Tae, Abhishek Sahu, Jong Hyun Lee
  • Patent number: 10962540
    Abstract: The present disclosure provides methods, reagents, systems, and devices that target ? lactamase as a biomarker for the sensitive and specific detection of tuberculosis-complex bacteria. Specifically, the present disclosure relates to methods and compositions for the detection of specific ?-lactamase protein and nucleic acid sequences to indicate the presence of tuberculosis-complex bacteria.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 30, 2021
    Assignee: The Texas A&M University System
    Inventors: Jeffrey D. Cirillo, Michael T. Norman
  • Patent number: 10948415
    Abstract: Methods for determining surgical margins using an imaging device are described that use multiple cameras to image a biological sample on a turntable bathed in white light or fluorescing due to a systemically administered dye. Fluorescence farther away from an excitation light source can be compensated upon determining a 3-D position of portions of the sample. The turntable is turned and tilted in order to take enough images to prepare an animation of the sample. In a graphical user interface, the animation can be stopped, zoomed, and tilted per a user's gesture, touch, tablet-tilting, or other commands. The image manipulation can be with touch gestures entered using a sterilizable or disposable touch pen.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: March 16, 2021
    Assignee: LI-COR, INC.
    Inventor: Han-Wei Wang
  • Patent number: 10918741
    Abstract: A PSMA-specific imaging agent comprising a compound according to formula I: are described, wherein S1 is an organic spacer group having from 5 to 30 carbons, A is an amino acid forming a portion of a negatively charged peptide oligomer, n is from 3 to 6, S2 is an organic spacer group having from 5 to 15 carbons, and I is an imaging group, and pharmaceutically acceptable salts thereof. The PSMA-specific imaging agents can be used to image PSMA within a tissue region to guide the treatment of diseases such as prostate cancer.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: February 16, 2021
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Steve Shih-Lin Huang, Warren D. Heston, Xinning Wang
  • Patent number: 10913855
    Abstract: Quenchers of the related art do not have a quenching ability high enough to sufficiently inhibit the emission of fluorescence from fluorescence compounds. Therefore, the present invention aims to provide a quencher which can sufficiently quench the fluorescence from fluorescent compounds including xanthene-based dyes. The present invention relates to a quencher formed of a compound represented by the following general formula (1), and the like.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: February 9, 2021
    Assignee: FUJIFILM Wako Pure Chemical Corporation
    Inventors: Katsufumi Suzuki, Tetsuji Murase, Shigeaki Imazeki
  • Patent number: 10888531
    Abstract: The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: January 12, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: George Mihov, Guy Draaisma, Silvana Rensina Antonnietta Di Silvestre, Tristan Handels
  • Patent number: 10883998
    Abstract: The present invention relates to methods and products associated with in vivo enzyme profiling. In particular, the invention relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. The invention also relates to products, kits, and databases for use in the methods of the invention.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: January 5, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Sangeeta N. Bhatia, Geoffrey A. von Maltzahn, Gabriel A. Kwong
  • Patent number: 10829727
    Abstract: Described herein are a system, device, methods and compositions related to generating 3-dimensional cardiac tissues. Also described herein are a system, device, and methods of maturing 3-dimensional cardiac tissues and maintaining their viability in culture.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: November 10, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Christopher S. Chen, Rebeccah Luu, Anant Chopra
  • Patent number: 10813563
    Abstract: Fluorescence based tracking of a light-emitting marker in a bodily fluid stream is conducted by: providing a light-emitting marker into a fluid stream; establishing field of view monitoring by placement of a sensor, such as a high speed camera, at a region of interest; recording image data of light emitted by the marker at the region of interest; determining time characteristics of the light output of the marker traversing the field of view; and calculating flow characteristics based on the time characteristics. Furthermore generating a velocity vector map may be conducted using a cross correlation technique, leading and falling edge considerations, subtraction, and/or thresholding.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: October 27, 2020
    Assignee: SCINOVIA CORP.
    Inventors: James Bradley Sund, Sr., David S. Cohen
  • Patent number: 10792377
    Abstract: A compound, a method of imaging a cell, and a method of detecting a cancer, an inflammatory disease, or a neoplastic disease are provided. The compound includes a nitroxide derivative of a fluorophore that is activatable upon exposure to free radicals. The method of imaging a cell includes contacting the cell with an activatable nitroxide derivative of a fluorophore. The method of detecting a cancer, an inflammatory disease, or a neoplastic disease includes administering an activatable nitroxide derivative of a fluorophore and then imaging one or more cells contacted with the compound.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: October 6, 2020
    Assignee: Vanderbilt University
    Inventors: Jashim Uddin, Brenda C. Crews, Lawrence J. Marnett
  • Patent number: 10758631
    Abstract: Polymorphs of Formula I, which is 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate and methods of making are provided. A method for organ imaging, comprising administering to a subject, a diagnostic effective amount of a composition comprising a polymorph of Formula I are also provided. In one embodiment, the organ includes one or more of kidney, bladder, ureter, urethra, bile ducts, liver, and gall bladder.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: September 1, 2020
    Assignee: LI-COR, INC.
    Inventors: Vassil Elitzin, William M. Volcheck, Katie Schaepe, Rahul Patil
  • Patent number: 10753941
    Abstract: The development of fluorescent bioprobes comprising organic fluorescent compounds that exhibit aggregation induced emission (AIE) properties, methods of producing the same, and their practical applications for in vitro and in vivo bioimaging.
    Type: Grant
    Filed: September 3, 2012
    Date of Patent: August 25, 2020
    Assignees: The Hong Kong University of Science and Technology, National University of Singapore
    Inventors: Benzhong Tang, Wei Qin, Jianzhao Liu, Sijie Chen, Tsz Kin Kwok, Bin Liu, Kai Li, Dan Ding, Haibin Shi, Jun Long Geng, Jingzhi Sun, Anjun Qin, Qiuli Zhao
  • Patent number: 10743770
    Abstract: A photoacoustic device comprises a light source configured to generate first and second lights; an irradiation unit configured to generate a first acoustic wave from an object including a contrast agent by irradiating the object with the first light, and then bleach the contrast agent by irradiating the object with the second light and generate a second acoustic wave from the object by irradiating the object with the first light after bleaching; a receiving unit configured to output a first signal upon receiving the first acoustic wave and output a second signal upon receiving the second acoustic wave; and an acquisition unit configured to acquire first information based on the first signal, and acquire second information based on the second signal.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: August 18, 2020
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Kengo Kanazaki, Tatsuki Fukui, Satoshi Yuasa
  • Patent number: 10709391
    Abstract: Body-mountable devices are provided to detect the presence or status of a tumor in a body by detecting probes associated with circulating cells of the tumor that travel to subsurface vasculature of the body. The probe enters a tumor and associates with cells of the tumor before the cells metastasize. A wearable body-mountable device can be worn for a protracted period of time to detect the probe associated with circulating tumor cells in the vasculature at low concentrations and/or at low rates. A body-mounted device could detect the presence of such released, tumor-cell-associated probes to determine a presence or status of a tumor in the body.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: July 14, 2020
    Assignee: Verily Life Sciences LLC
    Inventors: Alberto Clemente Vitari, Andrew Homyk, Joshua Simon Klein, Marija Pavlovic, Jerrod Joseph Schwartz
  • Patent number: 10712322
    Abstract: The present invention provides methods for analyzing compositions of polypeptides such as antibodies by ionic strength-mediated pH gradient ion exchange chromatography. In some aspects, the methods use a combination of pH gradients and ionic strength gradients to separate the polypeptide from charge variants of the polypeptide. In some aspects, the methods use a stable ionic strength to optimize the pH gradient separation window to separate the polypeptide from charge variants. Such methods are useful for analyzing polypeptide, e.g. antibodies, with a pI greater than 9 or a pI less than 7. In some aspects, the invention provides a multiproduct method for the analysis of polypeptides of varying pI's.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: July 14, 2020
    Assignee: Genentech, Inc.
    Inventors: Yajun Wang, George Tony Moreno, Boyan Zhang, Liangyi Zhang, Dell Farnan, Thomas Patapoff
  • Patent number: 10697950
    Abstract: Disclosed herein is a fluorescent compound represented by the following general formula and having fluorescence characteristics that vary in the presence of a subject substance, wherein R1 and R2 each independently represent a carboxyl group, or a substituent containing a carboxyl group, and R3 and R4 each independently represent a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxyl group, a carboxyl group, or a substituent containing a carboxyl group.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: June 30, 2020
    Assignees: KABUSHIKI KAISHA TOSHIBA, TOSHIBA TEC KABUSHIKI KAISHA
    Inventors: Hiroki Iwanaga, Ryozo Akiyama
  • Patent number: 10676840
    Abstract: The method is a method of evaluating a manufacturing process of a silicon material, wherein the manufacturing process includes a process that uses a member containing a carbon-containing sintered body, and the method of evaluating the manufacturing process of a silicon material includes performing DLTS measurement on a silicon material manufactured in the manufacturing process, and estimating a heavy metal contamination source of a silicon material manufactured in the manufacturing process with an indicator in the form of presence/absence of detection of a peak of a carbon-related level and presence/absence of detection of a peak of a heavy metal-related level in a DLTS spectrum obtained by the DLTS measurement.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: June 9, 2020
    Assignee: SUMCO CORPORATION
    Inventors: Noritomo Mitsugi, Kazutaka Eriguchi, Shuichi Samata, Ayumi Masada
  • Patent number: 10675242
    Abstract: The object of the invention is to elevate the stability of an aqueous formulation comprising ALAs and an iron compound. The present invention provides an aqueous formulation comprising ALAs and an iron compound, characterized in that it further comprises 0.2-30% by weight of salts, said salts are sodium salts or potassium salts, and the pH of said aqueous formulation is 2-8.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 9, 2020
    Assignee: SBI PHARMACEUTICALS, CO., LTD.
    Inventors: Mika Morishita, Urara Ota, Masahiro Ishizuka
  • Patent number: 10656092
    Abstract: A method of quantifying a specific biological material in a specimen stained using fluorescent dye accumulating particles capable of binding to the material includes: inputting a first fluorescence image obtained by capturing an image of the specimen; extracting a certain region from the first fluorescence image and calculating a first luminance integrated value by integrating luminance values of the certain region; and calculating the number of the particles included in the certain region from the first luminance integrated value and an average luminance value per fluorescent dye accumulating particle, wherein the average luminance value is calculated from a distribution of second luminance integrated values obtained by integrating luminance values for individual bright spot regions, which indicate emission of light by the fluorescent dye accumulating particles, in a second fluorescence image obtained by capturing an image of a preparation onto which the fluorescent dye accumulating particles are dispersed w
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: May 19, 2020
    Assignee: Konica Minolta, Inc.
    Inventors: Yuichi Ozaki, Kensaku Takanashi, Daisuke Tomioka
  • Patent number: 10646591
    Abstract: Disclosed are imaging agents having the following Formula I: wherein F is a near infrared fluorophore, S is an enzymatically cleavable oligopeptide, Q is a fluorescence quencher molecule, and M is a moiety selected from the group consisting of PEG or derivative thereof and a targeting ligand, and wherein F, Q and M are linked to separate amino acids of the enzymatically cleavable oligopeptide. Compositions comprising such compounds, as well as methods of use, methods of identifying a cell or a population of cells in vivo expressing a protease of interest, and methods of treating a disease through imaging are also disclosed.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: May 12, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Xiaoyuan Chen, Seulki Lee, Lei Zhu
  • Patent number: 10563198
    Abstract: Antisense oligonucleotides capable of preventing or reducing exon 73 inclusion into the human COL7A mRNA are characterized in various ways: (a) the oligonucleotide's sequence includes at most two CpG sequences; (b) the oligonucleotide has a length of no more than 24 nucleotides; (c) the oligonucleotide is capable of annealing to the (SRp40/SC35 binding/ESE) element in exon73. These oligonucleotides can usefully be oligoribonucleotides with modified internucleosidic linkages e.g. phosphorothioate linkages.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: February 18, 2020
    Assignee: WINGS THERAPEUTICS, INC.
    Inventors: Elisabeth Marlene Haisma, Marko Potman, Wouter Beumer, Vera Brinks